| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109485732-B |
| titleOfInvention |
Genetically engineered dual-target chimeric antigen receptor and its use |
| abstract |
The invention belongs to the field of genetic engineering, and in particular relates to a double-target chimeric antigen receptor modified by genetic engineering. Aiming at the phenomenon that the PD-L1 expression of tumor cells and immune cells is up-regulated after tumor cells are exposed to serous cavity effusion, the present invention provides a genetically modified dual-target chimeric antigen receptor and a host cell thereof. The dual-target chimeric antigen receptor of the present invention will compete for binding to PD-L1, convert the inhibitory signal of PD-L1 into an activation signal, and enhance the killing activity of T cells, and at the same time, the 4-1BB introduced downstream can promote T cells Proliferate and survive. The present invention also discloses host cells expressing the above-mentioned dual-target antigen receptors and their use in preventing or treating malignant tumors/solid tumors. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |